December 3, 2020 07:10 AM ESTUpdated 12:51 PM
R&D

Jaz­z's $1B SCLC drug fails com­bo tri­al, quash­ing hopes of quick full ap­proval. But how much does it mat­ter?

Amber Tong

Lur­binecte­din was look­ing like a great turn­around sto­ry for Span­ish biotech Phar­ma­Mar. More than a year af­ter the drug flopped in a Phase III …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times